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The aim of this study was to investigate the effect of levothyroxine (LT4) replacement therapy during three months on some
parameters of metabolic syndrome and atherosclerosis in patients with increased thyroid-stimulating hormone (TSH) level. This
study included a group of 30 female patients with TSH level >4mIU/L and 15 matched healthy controls. Intima media complex
thickness (IMCT) and peak systolic flow velocity (PSFV) of superficial femoral artery were determined by Color Doppler scan. In
hypothyroid subjects, BMI, SBP, DBP, and TSHwere significantly increased versus controls and decreased after LT4 administration.
FT4 was significantly lower in hypothyroid subjects compared with controls and significantly higher by treatment. TC, Tg, HDL-
C, and LDL-C were similar to controls at baseline but TC and LDL-C were significantly decreased by LH4 treatment. IMCT was
significantly increased versus controls at baseline and significantly reduced by treatment. PSFV was similar to controls at baseline
and significantly decreased on treatment. In this study, we have demonstrated the effects of LT4 replacement therapy during three
months of treatment on correction of risk factors of metabolic syndrome and atherosclerosis.
1. Introduction
Hypothyroidism is a clinical syndrome caused by thyroid hor-
mone (TH) deficiency, due to reduced production, deranged
distribution, or lack of TH effects [1, 2]. Hypothyroidism is
characterized by decreased metabolic rate and by a serum
thyroid-stimulating hormone (TSH) above the upper refer-
ence limit [3].
The most common form of TH replacement therapy
is synthetic T4 hormone, which is generally known as
levothyroxine (LT4) and it is used to suppress TSH. While
some experts highlight benefits of LT4 replacement therapy,
others point out the harmful effects of the above mentioned
therapy [4–7].
According to the severity, hypothyroidism is divided into
severe or clinical and mild or subclinical hypothyroidism
(SH). SH represents a condition of mild to moderate thyroid
failure characterized by normal levels of TH with mildly
elevated TSH concentrations, with or without clinical symp-
toms [8–10]. Further, SH can be divided into two categories,
depending on the magnitude of the increase in serum TSH
level, with concentrations of 4.5–10mU/L considered as
a mild disease and with concentration of TSH >10mU/L
considered as a severe disease [4, 11].
Treating patients with increased TSH level, with LT4,
decreases the rate of cardiovascular (CV) diseases. Some
studies have not shown any benefits of LT4 replacement
therapy in reducing CV morbidity and mortality [10, 12–14].
Atherosclerosis is a leading cause of mortality and
morbidity in the modern world. Atherosclerosis can cause
ischemic heart disease, stroke, or intermittent claudication
and gangrene [15–17]. Atherosclerotic lesions commonly
develop at arterial branch sites, in regions of flowdisturbance.
In most cases, there is a long period of silent, slowly
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progressive coronary atherosclerosis before these disorders
become manifest. Risk factors for atherosclerosis include
insulin resistance, dyslipidemia, central and visceral obesity,
hypertension, endothelial dysfunction, smoking, and physi-
cal inactivity. Intima media complex thickness (IMCT) and
peak systolic flow velocity (PSFV) are commonly used as a
marker of atherosclerosis [18].
Hypothyroidism is associated with factors of metabolic
syndrome such as dyslipidemia, hypertension, obesity, and
often insulin resistance. All these factors directly contribute
to accelerated atherosclerosis [19]. Some studies show asso-
ciation between hypothyroidism and ischemic heart disease,
regardless of age, systolic blood pressure (SBP), body mass
index (BMI), and total cholesterol (TC) [20], while some do
not show the relationship between increased TSH and heart
disease [12].
Hypothyroidism is one of the most common causes of
secondary dyslipidemia [21]. It has been reported that 95%
of newly diagnosed hypothyroid patients have increased
level of cholesterol [13, 22–24] and 5% of hypothyroid
patients have hypertriglyceridemia. Hypothyroidism leads
to a decreased level of the low density lipoproteins (LDL)
receptor expression on fibroblasts and hepatocytes, decreased
LDL-cholesterol (LDL-C) uptake, and consequent increase in
serum LDL-C levels [13, 23].
The relationship betweenhypothyroidismand atheroscle-
rosis has been confirmed [25–27]. Understanding the effects
of hypothyroidism on morphological and hemodynamic
parameters of the functional status of blood vessels, as an
indicator of early atherosclerosis, is of great importance in
terms of timely introduction of LT4 replacement therapy.
Thus, the aim of this study was to investigate a possible
correlation between some parameters of metabolic syndrome
and atherosclerosis with increased TSH and to investigate the
effect of LT4 replacement therapy on lipid profile, IMCT, and
PSFV in patients diagnosed with hypothyroidism.
2. Material and Methods
2.1. Subjects and Method. This study was performed in
the Department of Endocrinology, Diabetes and Metabolic
Disorders of Clinical Center (KBC) Zemun, Serbia, during
2009.The study included 45 female subjects, divided into two
groups: a group of patients (30 subjects) with newly diag-
nosed hypothyroidism, with TSH level >4mIU/L, labeled as
HypoT, and a control group labeled as control, consisting
of 15 euthyroid subjects, age and gender matched with the
patient group. Control subjects were healthy volunteer blood
donors, recruited after physical exam, with no history of any
disease. None of the controls were taking any drugs affecting
the levels of serum TH and lipid levels or the acceleration of
atherosclerosis. From each subject, multiple serum samples
were obtained after an overnight fast.The study was approved
by the Local Ethics Committee of the Clinical Center Zemun
and informed consent was obtained from all subjects who
participated in this study.
Initially, at the time of the detection of thyroid dysfunc-
tion in the study group (HypoT group) and the consequent
initiation of LT4 treatment, parameters of the metabolic
syndrome (BMI, SBP, diastolic blood pressure (DBP), and
lipid levels) were assessed. Subjects were subjected to Color
Doppler scan of the lower-limbs blood vessels, right super-
ficial femoral artery (SFA), in order to determine mor-
phological and hemodynamic parameters: the IMCT and
PSFV. Dose of LT4 was calculated according to the body
mass, less than 1 𝜇g/kg BM for subjects with TSH levels
<10mIU/mL (average dose 50 (12,5–75)𝜇g) or 1–1,5𝜇g/kg
BM for subjects with TSH levels >10mIU/mL (average dose
75 (50–150)𝜇g). In the cases of higher calculated doses,
LT4 was gradually increased in weekly intervals. Treated
subjects who did not attain reference TSH value during 3
months of treatmentwere excluded from the study (neglected
number). After three months of LT4 substitution therapy and
established laboratory euthyroidism (labeled as LT4 group),
to all patients the same hormonal and metabolic parameters
were assessed.
2.2. Anthropometric and Clinical Measurements. Body mass
index (BMI) was calculated as a body mass (kg) divided by
the square of their height (m2). Body mass measurements
were performed using calibrated beam-type balance with
the subject wearing light indoor clothes and no shoes and
recorded to the nearest 0.1 kg. Body height was measured
using Harpenden Anthropometer (Holtain Ltd., Croswell,
UK). Values for SBP and DBP were obtained using the
same sphygmomanometer (HS 201C1 Palm Type Sphygmo-
manometer, Wenzhou Hongshun Industries and Trade Co.),
a standard mechanical pressure gauge, measuring on the left
upper arm standard procedure. The same person performed
the same procedure to each subject: triple measurement with
intervals of 10 minutes. Values are expressed in millimeters
of mercury (mmHg). From obtained values, mean value was
calculated and furthermore statistically used.
2.3. Determination of Serum TSH and FT4 Concentrations.
Measurements of TH concentrations were carried out in
biochemical laboratory of KBC Zemun. Levels of TSH and
free thyroxine (FT4) in serum were determined by Immulite
2000 [28]. Immulite method is a chemiluminescent enzyme
immunometric assay, where serum sample and a ligand-
labeled tracer are added to a test unit containing a polystyrene
bead coated with an antibody specific to the analyte to be
measured. After incubation, the test samples underwent a
washing step; an antiligand enzyme is then introduced and
the test samples underwent the second incubation, after
which unbound enzyme was removed. Then, a substrate
is added, which in the presence of the enzyme produces
emission of photons, measured by the Immulite instrument,
and converted into concentration. Reference values for TSH
and FT4 were 0.4–4.0mIU/L and 10–22 pmol/L, respectively.
2.4. Determination of Serum, Total Cholesterol (TC), Triglyc-
eride (Tg), HDL-Cholesterol, and LDL-Cholesterol Levels.
Concentrations of TC, triglyceride (Tg), and high density
lipoproteins-cholesterol (HDL-C) in serum were measured
on Instrumentation Laboratory autoanalyzer using enzy-
matic assays (Instrumentation Lab, MA, USA) [29, 30]. The
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Table 1: Basic clinical parameters in control and hypothyroid patients before (HypoT) and after treatment with LT4 (LT4).
Basic clinical parameters Study groups 𝑃 value(𝑡-test)Control HypoT LT4
Age [year]
[𝑋 ± SD (min–max)]
44 ± 10
(29–61)
49 ± 10
(28–64)
49 ± 10
(28–64) N.S.
BMI [kg/m2]
[𝑋 ± SD (min–max)]
25.65 ± 2.9
(21.5–38.9)
28.47 ± 4.1
(21.6–37.9)
27.68 ± 4.0
(20.2–36.4)
<0.05∗
<0.001###
SBP [mmHg]
[𝑋 ± SD (min–max)]
121 ± 14
(100–150)
138 ± 25
(100–210)
118 ± 17
(90–170)
<0.01∗∗
<0.001###
DBP [mmHg]
[𝑋 ± SD (min–max)]
80 ± 10
(70–100)
88 ± 13
(70–120)
74 ± 9
(60–100)
<0.05∗
<0.001###
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HypoT: hypothyroid patients, and LT4: patients after treatment with LT4.
Values are given as mean ± SD; ∗𝑃 < 0.05; ∗∗𝑃 < 0.01. ∗ represents significance between control and hypothyroid patients before treatment; ###𝑃 < 0.001. #
represents significance between hypothyroid patients before and after treatment.
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Figure 1: (a) Levels of thyroid-stimulating hormone (TSH) and (b) free thyroxine (FT4), in control and hypothyroid patients before (HypoT)
and after treatment with LT4 (LT4). Values are given as mean ± SD.
values of LDL-C were calculated using Friedewald’s equation
[31] (LDL-C = TC-HDL-C − 0,45 ∗ TG mmol/L). TC,
Tg, HDL-C, and LDL-C concentrations were expressed as
mmol/L. The reference values for TC, Tg, HDL-C, and LDL-
C were 3.6–5.1, <1.7, >1.1, and <3.2 in mmol/L, respectively.
2.5. Color Doppler Imaging of Lower-Limb Arteries. Duplex
Color Doppler scans of right SFA were made using the
“Acuson” 7.5MHz linear transducer. After marking the right
SFA, the thickness of the IMC (normally up to 1.1mm in
carotid artery) and the PSFV (in m/s) was measured.
2.6. Statistical Analyses. The Statistical Package for the Social
Sciences (SPSS) 12.0 (SPSS Inc., Chicago, Illinois) statistical
software package was used for all statistical calculations. Data
are presented as mean ± standard deviation for continuous
variables. Differences between each group were analyzed
by Student’s 𝑡-test and chi-square test. Linear correlation
analysis (Spearman andPearson)was used to test correlations
between changes of IMCT and BMI as well as levels of TSH,
FT4, SBP, DBP, TC, Tg, HDL-C, and LDL-C. A 𝑃 < 0.05 (2-
tailed) was considered significant.
3. Results
The clinical and metabolic parameters of hypothyroid and
euthyroid control subjects are presented in Table 1.Themean
age of hypothyroid subjects was not significantly different
compared with euthyroid subjects.
Hypothyroid subjects have significantly higher BMI (𝑃 <
0.05), SBP (𝑃 < 0.01), and DBP (𝑃 < 0.05) compared with
control subjects (Table 1). The level of TSH was significantly
higher (𝑃 < 0.001) (Figure 1(a)) and the level of FT4 was
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Figure 2: Lipid profiles: (a) total cholesterol (TC), (b) triglyceride (Tg), (c) high density lipoproteins-cholesterol (HDL-C), and (d) lowdensity
lipoproteins-cholesterol (LDL-C) of control and hypothyroid patients before (HypoT) and after treatment with LT4 (LT4). Values are given
as mean ± SD. N.S.: nonsignificant.
significantly lower (𝑃 < 0.001) (Figure 1(b)) in hypothyroid
subjects compared with control subjects. No significant
changes in TC, Tg, HDL-C, and LDL-C levels between
hypothyroid and control subjects (Figure 2) were observed.
After TH replacement with LT4, in hypothyroid subjects,
the values of BMI (𝑃 < 0.001), SBP (𝑃 < 0.001), and DBP
(𝑃 < 0.001) were significantly decreased (Table 1). Further-
more, TSH level was significantly decreased (𝑃 < 0.001)
(Figure 1(a)), and the level of FT4 was significantly increased
(𝑃 < 0.001) (Figure 1(b)) in LT4-treated patients compared
with hypothyroid subjects. The concentrations of TC (𝑃 <
0.01) and LDL-C (𝑃 < 0.001) were significantly decreased,
with no changes in the level of Tg and HDL-C after hormone
replacement (Figure 2).
The main initial IMCT on the beginning of right SFA
was significantly increased (𝑃 < 0.001) (Figure 3(a)) with
no significant changes of PSFV (Figure 3(b)) in hypothyroid
subjects compared with controls. After LT4 therapy, the
values for IMCT on the beginning of right SFA (𝑃 < 0.001)
and the PSFV (𝑃 < 0.05) were significantly decreased
comparedwith the values before hormone treatment (Figures
3(a) and 3(b)).
Results obtained by linear relationship analysis between
IMCT and BMI, as well as levels of TSH, FT4, SBP, DBP, Tg,
TC, HDL-C, and LDL-C before and after LT4 replacement
treatment, show statistically significant correlations between
IMCT and TSH (𝜌 = 0.584; 𝑃 < 0.01) (Figure 4(a)), FT4
(𝑟 = −0.471; 𝑃 < 0.01) (Figure 4(b)), and DBP before (𝑟 =
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Figure 3: (a) Intima media complex thickness (IMCT) and (b) peak systolic flow velocity (PSFV) in control and hypothyroid patients before
(HypoT) and after treatment with LT4 (LT4). Values are given as mean ± SD.
0.358; 𝑃 < 0.05) (Figure 4(c)) and IMCT and DBP after LT4
replacement treatment (Figure 4(d)).
4. Discussion
In this study we have demonstrated the effects of LT4
replacement therapy during three months of treatment,
on correction of risk factors for metabolic syndrome and
atherosclerosis. Our results show significant effects of LT4
administration on BMI, SBP, DBP, TSH, FT4, TC, LDL-C,
IMCT, and PSFV, with no significant changes of Tg and
HDL-C in hypothyroid patients. In our study, patients with
newly diagnosed hypothyroidism have significantly different
BMI, DBP, SBP (Table 1), TSH, FT4 (Figure 1), and IMCT
(Figure 3(a)), with no significant difference in lipid profile
(Figure 2) and PSFV (Figure 3(b)) compared with controls.
Nonsignificant difference between hypothyroid and control
groups in relation to the lipid profile could be explained by the
relatively high levels of lipids in the group of control subjects.
We did not observe a correlation between TSH and FT4
and lipid parameters (Tg, TC, HDL-C, and LDL-C) and
PSFV.On the contrary,we have observed a significant positive
correlation of TSH and a negative correlation between FT4
levels and the IMCT in hypothyroid group before LT4
treatment (Figure 4). Significant correlation between TSH
level and lipid profile was not found probably due to some
other parameters, that is, age and diet effects on lipid levels
[32, 33]. Another possibility could be because of small sample
size and small effect size. In addition, therewere no significant
correlations between BMI, lipid, TSH, and FT4 and PSFV.
BMI and lipid profile have no significant effect on IMCT, and
this could be explained by the statistical homogeneity of lipids
between the groups. Our results also show the significant
positive effect of DBP on IMCT (Figure 4), while BMI has
no effect on IMCT.
In our study, we did not investigate the etiology of the
hypothyroidism, since it is well known that Hashimoto’s
thyroiditis is the most common cause of increased TSH
level. Stamatelopoulos et al. [34] reported that Hashimoto’s
thyroiditis is associated with an increased carotid-femoral
PSFV independent of arterial atheromatosis indicating a
direct effect on arterial stiffness. It is possible that hemody-
namic consequences occurred firstly due to arterial stiffening
which was followed by thickening of the IMCT. Jorde et
al. suggest that the thickening of IMCT in patients with
thyroid hypofunction is an early feature of atherosclerosis and
that healthy controls show no significant correlation between
IMCT and TSH [35]. Studies in a large Japanese population
show association between thyroid function and IMCT in
euthyroid individuals too [36]. Furthermore, in euthyroid
persons IMCT is associated with FT4 after control of clinical
factors, lipid levels, and thyroid autoantibodies [37].
The increase in TSHmay be associated with an increased
morbidity from CV disease and decrease of myocardial
contractility [12].The importance of treating hypothyroidism
includes the correction of patients’ lipid profile [38], too.
A positive effect of thyroid substitution on the level of
lipid fractions and reduced risk of coronary heart disease
is shown in hypothyroid patients [39–43]. Thyroid function
is reversible after LT4 treatment. Postmortem and epidemi-
ological data show an increase in vascular risk in treated
hypothyroid patients [44]. CV changes are reversible after
euthyroid state is reached. Early initiation of the treatment of
SH with LT4 can reduce cholesterol level but also may lead to
development orworsening of existing coronary artery disease
or to arrhythmias [12]. Some studies indicate the absence of
lipid correction after substitution therapy with LT4 [41, 45].
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Figure 4: Correlation analyses between intima media complex thickness (IMCT) and (a) thyroid-stimulating hormone (TSH), (b) free
thyroxine (FT4), and (c) diastolic blood pressure (DBP) before and (d) DBP after LT4 replacement treatment; 𝑟 indicates Pearson correlation
coefficient; 𝜌 indicates Spearman rank correlation.
Our results indicate a significant correction of atheroscle-
rosis risk factors after three months of therapy with LT4.
After TH replacement in hypothyroid subjects the values
for BMI, SBP, DBP (Table 1), TC, and LDL-C (Figure 2)
were significantly decreased compared with the values before
treatment. Similar results are reported after six months of
LT4 treatment, when significant reductions of TC, LDL,
and IMCT (11%) in the carotid artery are reported [46].
The degree of improvement in lipid levels after biochemical
euthyroidism is achieved with LT4 therapy and depends on
the severity and duration of the thyroid dysfunction as well
as the degree of hypercholesterolemia before the treatment
[12, 24, 47]. In addition, diet, initial BMI, and smoking habits
primarily could affect the level of LDL-C [48].When the level
of TSH was higher than 10mIU/L, replacement therapy with
LT4 reduced the levels of TC and LDL-C [13, 24].
More controversial is the impact of treatment with LT4
on HDL-C in hypothyroid patients. Some studies show
an increase in HDL-C levels after LT4 treatment [41, 49]
and others show a decrease [50, 51], whereas some studies
show absence of the influence of substitutions on HDL-C
level [45, 52]. Our results show that Tg and HDL-C levels
were not significantly changed after hormone replacement in
hypothyroid subjects (Figure 2). Meta-analysis of 13 studies
shows that there was no effect of substitution on the level
of HDL-C and Tg [13]. In SH patients, application of LT4
substitution caused a decline in TC (in 11 of 13 studies), while
in 7 of the 9 studies there was a decrease in LDL-C [53].
These results support the hypothesis that treatment of SH is
due to the favorable effect of substitution on lipid status, thus
reducing the risk of coronary heart disease [12, 13, 53]. Still
it is not clear to what degree treatment of SH reduces CV
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morbidity [53]. LT4 treatment usually corrects dyslipidemia,
but if not, it is most likely that primary hyperlipidemia is
associated with elevated TSH level [22].
After TH replacement in hypothyroid subjects the values
for IMCT (Figure 3(a)) and PSFV (Figure 3(b)) were signifi-
cantly decreased compared with the values before treatment
with hormone. A significant decrease in IMCT is probably
accompanied with the fall of TC and TSH. Thus, the arterial
wall changes occur early with increase of TSH and LT4
treatment improving the lipid profile and decreasing IMCT.
Taken together, these results suggest that the lipid infiltration
of the arterial wall may be the principle mechanism of IMCT
thickening [46].
In conclusion, we reported significant metabolic effects
of LT4 replacement therapy in hypothyroid patients. Our
study is the first to examine the effects of LT4 on factors of
metabolic syndrome and atherosclerosis. The improvement
of IMCT in hypothyroid patients after LT4 therapy could
contribute to reduced CV risk in this patient population.
The limitation of our study is a small number of hypothy-
roid and healthy subjects. Given that our study included
a small number of subjects, we are not able to completely
show the effects of replacement therapy. Future studies on a
larger population size are needed to elucidate the effects of
hypothyroidism on IMCT and PSFV.This is the first phase of
a prospective plot study to examine the effects on LT4 therapy
on lipid and hemodynamic andmorphological parameters, in
Serbian population.
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